Navigation Links
Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

WALTHAM, Mass., Aug. 11, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Wedbush Securities Life Sciences Management Access Conference at the Le Parker Meridien Hotel, 119 West 56th Street in New York City. The presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. (EDT) in the Lorica Room, located on the second floor.  

Interleukin's management team will be available for one-on-one meetings with investors participating in the Wedbush Securities Life Sciences Management Access Conference.

The presentation will be webcast live at http://www.wsw.com/webcast/wedbush17/iliu/ where it will also be archived for 90 days. The webcast link will also be available through Interleukin's website at http://www.ilgenetics.com.

About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
2. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
3. Interleukin Genetics Reports Fourth Quarter and Year End 2010 Financial Results
4. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
5. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
6. Interleukin Genetics to Present at Upcoming Biotech Industry Meetings
7. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
8. Continued Uptake of TNF-Alpha Inhibitors and Interleukin Inhibitors Will Drive $2.2 Billion Growth in the Psoriasis Drug Market
9. Interleukin Genetics Reports Second Quarter 2009 Financial Results
10. Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results
11. Interleukin Genetics to Present at the 2009 BIO Business Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Research and Markets  has announced the addition ... Services, End-User , Application - Global Forecast to 2019" ... global oligonucleotide synthesis market is expected to reach $1,712.1 ... at a CAGR of 9.8% from 2014 to 2019. ... basis of products and services, applications, end users, and ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
(Date:9/29/2014)... Transparency Market Research, in its report titled ... by Application - Cancer, Metabolic, CVS, CNS & others, ... - Global Industry Analysis, Size, Share, Growth, Trends and ... therapeutics market was worth US$14.1 billion in 2011 and ... an 8.7% CAGR. , The two main types of ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Smart, eco-friendly new battery to solve problems 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... MA (July 20, 2011)A consortium led by scientists at the ... world,s most detailed genetic map. A genetic map ... sperm or egg where the DNA from the mother and ... reproductive cell. The biological process whereby this reshuffling occurs is ...
... (Nasdaq: SGMO ) today announced that the company ... July 27, 2011, after the market closes. The press release ... ET, which will be open to the public via telephone ... the financial results and discuss other business matters. ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
Cached Biology Technology:Researchers create the world's most advanced genetic map 2Researchers create the world's most advanced genetic map 3Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4
(Date:9/29/2014)... significant anti-tumour activity in patients with advanced BRAF ... has progressed after chemotherapy, according to phase II ... Madrid, Spain. , "Reports of lung cancers ... because these mutations may be associated with increased ... author Dr David Planchard, pulmonary oncologist at the ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
... University of Massachusetts Amherst resource economist Sylvia Brandt, with colleagues ... upward for childhood asthma and for the first time include ... study released this week in the early online version of ... of asthma due to pollution is much higher than past ...
... The Department of Energy,s Pacific Northwest National Laboratory ... that improves research sample analysis to the marketplace. ... PNNL is receiving a 2012 award for Excellence ... network that encourages federal laboratories to transfer lab-developed ...
Cached Biology News:Biometrics Market in India 2010 - 2014 2Asthma rate and costs from traffic-related air pollution are much higher than once believed 2PNNL recognized for technology transfer 2
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... II (Dual-Stage Quadrupole) Thermo Scientific (Part ... in analytical instrumentation, introduces the latest product ... II. Based on the proven reliability and ... GC/MS systems, the DSQ II incorporates the ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: